Free Trial
NASDAQ:ARTL

Artelo Biosciences Q4 2023 Earnings Report

Artelo Biosciences logo
$1.03 -0.13 (-11.21%)
Closing price 04/23/2025 04:00 PM Eastern
Extended Trading
$1.02 -0.01 (-0.87%)
As of 04/23/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artelo Biosciences EPS Results

Actual EPS
-$0.99
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.70
One Year Ago EPS
N/A

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 25, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Artelo Biosciences' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Artelo Biosciences Earnings Headlines

Artelo Biosciences (NASDAQ:ARTL) Trading Down 11.2% - Should You Sell?
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Artelo Biosciences announces new data on ART12.11
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL), a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

View Artelo Biosciences Profile

More Earnings Resources from MarketBeat